Literature DB >> 23408705

Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.

Mona K Beyer1, Guido Alves, Kristy S Hwang, Sona Babakchanian, Kolbjorn S Bronnick, Yi-Yu Chou, Turi O Dalaker, Martin W Kurz, Jan P Larsen, Johanne H Somme, Paul M Thompson, Ole-Bjørn Tysnes, Liana G Apostolova.   

Abstract

ParkWest is a large Norwegian multicenter study of newly diagnosed drug-naïve subjects with Parkinson's disease (PD). Cognitively normal PD subjects (PDCN) and PD subjects with mild cognitive impairment (PDMCI) from this cohort have significant hippocampal atrophy and ventricular enlargement, compared to normal controls. Here, we aimed to investigate whether the same structural changes are associated with cerebrospinal fluid (CSF) levels of amyloid beta (Aβ)38 , Aβ40 , Aβ42 , total tau (t-tau), and phosphorylated tau (p-tau). We performed three-dimensional radial distance analyses of the hippocampi and lateral ventricles using the MRI data from ParkWest subjects who provided CSF at baseline. Our sample consisted of 73 PDCN and 18 PDMCI subjects. We found significant associations between levels of all three CSF Aβ analytes and t-tau and lateral ventricular enlargement in the pooled sample. In the PDCN sample, all three amyloid analytes showed significant associations with the radial distance of the occipital and frontal horns of the lateral ventricles. CSF Aβ38 and Aβ42 showed negative associations, with enlargement in occipital and frontal horns of the lateral ventricles in the pooled sample, and a negative association with the occipital horns in PDMCI. CSF Aβ levels in early PD correlate with ventricular enlargement, previously associated with PD dementia. Therefore, CSF and MRI markers may help identify PD patients at high risk for developing cognitive decline and dementia in the course of their illness. Contrary to Alzheimer's disease, we found no associations between CSF t-tau and p-tau and hippocampal atrophy.
Copyright © 2013 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23408705      PMCID: PMC3608817          DOI: 10.1002/mds.25282

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  45 in total

1.  Magnetic resonance image tissue classification using a partial volume model.

Authors:  D W Shattuck; S R Sandor-Leahy; K A Schaper; D A Rottenberg; R M Leahy
Journal:  Neuroimage       Date:  2001-05       Impact factor: 6.556

2.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

3.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

4.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

5.  Visuospatial judgment. A clinical test.

Authors:  A L Benton; N R Varney; K D Hamsher
Journal:  Arch Neurol       Date:  1978-06

6.  Cognitive profile of patients with newly diagnosed Parkinson disease.

Authors:  Dino Muslimovic; Bart Post; Johannes D Speelman; Ben Schmand
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.

Authors:  Björn Holmberg; Bo Johnels; Kaj Blennow; Lars Rosengren
Journal:  Mov Disord       Date:  2003-02       Impact factor: 10.338

9.  Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.

Authors:  Per Selnes; Kaj Blennow; Henrik Zetterberg; Ramune Grambaite; Lars Rosengren; Lisbeth Johnsen; Vidar Stenset; Tormod Fladby
Journal:  Cerebrospinal Fluid Res       Date:  2010-07-30

10.  White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.

Authors:  Turi O Dalaker; Jan P Larsen; Michael G Dwyer; Dag Aarsland; Mona K Beyer; Guido Alves; Kolbjorn Bronnick; Ole-Bjorn Tysnes; Robert Zivadinov
Journal:  Neuroimage       Date:  2009-06-16       Impact factor: 6.556

View more
  15 in total

Review 1.  Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2017-08-14       Impact factor: 3.307

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 3.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.

Authors:  David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2013-07-31       Impact factor: 34.870

4.  An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.

Authors:  Marian Shahid; Jeehyun Kim; Katherine Leaver; Taylor Hendershott; Delphine Zhu; Brenna Cholerton; Victor W Henderson; Lu Tian; Kathleen L Poston
Journal:  Neurobiol Dis       Date:  2019-02-28       Impact factor: 5.996

5.  Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Authors:  Lynn M Bekris; Debby W Tsuang; Elaine R Peskind; Chang E Yu; Thomas J Montine; Jing Zhang; Cyrus P Zabetian; James B Leverenz
Journal:  Mov Disord       Date:  2015-03-24       Impact factor: 10.338

6.  Language-general and -specific white matter microstructural bases for reading.

Authors:  Mingxia Zhang; Chuansheng Chen; Gui Xue; Zhong-Lin Lu; Leilei Mei; Hongli Xue; Miao Wei; Qinghua He; Jin Li; Qi Dong
Journal:  Neuroimage       Date:  2014-05-09       Impact factor: 6.556

7.  Mice deficient in transmembrane prostatic acid phosphatase display increased GABAergic transmission and neurological alterations.

Authors:  Heidi O Nousiainen; Ileana B Quintero; Timo T Myöhänen; Vootele Voikar; Jelena Mijatovic; Mikael Segerstråle; Annakaisa M Herrala; Natalia Kulesskaya; Anitta E Pulkka; Tanja Kivinummi; Usama Abo-Ramadan; Tomi Taira; T Petteri Piepponen; Heikki Rauvala; Pirkko Vihko
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

Review 8.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

9.  Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population.

Authors:  Johannes Lange; Kristin Aaser Lunde; Camilla Sletten; Simon Geir Møller; Ole-Bjørn Tysnes; Guido Alves; Jan Petter Larsen; Jodi Maple-Grødem
Journal:  Parkinsons Dis       Date:  2015-12-14

Review 10.  Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.

Authors:  Paulina Gonzalez-Latapi; Ece Bayram; Irene Litvan; Connie Marras
Journal:  Behav Sci (Basel)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.